Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia

Abstract

Background: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the world. CLL involves the abnormal activation of Wingless-type (Wnt) signaling pathway. Lymphoid enhancer-binding factor 1 (LEF1) is a member of the LEF1/T-cell factor (TCF) family of transcription factors. The aim of the current study is to evaluate LEF1 expression in CLL and its impact on risk stratification and response to therapy. Methods: This study was conducted on 32 patients recently diagnosed as chronic lymphocytic leukemia. Complete blood picture, LDH, bone marrow aspiration, immunophenotyping, cytogenetic analysis and assessment of LEF1 expression by real time PCR were done For all patients. Results: The prognostic value for LEF1 was evaluated. There was a significant difference between Low LEF1 group and high LEF1 group as regards mortality (P .006); all the patients in low LEF1 group were alive at the end of follow up period, while in high LEF1 group five were alive at the end of follow up period and two died during the study. The overall survival of patient's low LEF1 level was longer than patients with high LEF1 level. Such difference was statistically significant (P=0.005). Conclusion: Level of expression of LEF1 in CLL patients may be valuable in predicting the survival.